Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS.

Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.

2.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

3.

Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer.

Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, Eble MJ.

Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):83-9. Epub 2007 Sep 12.

PMID:
17855010
4.

Laparoscopic radical prostatectomy: surgical, oncological and functional outcomes.

Nisen H, Perttilä I, Ranta-Knuuttila T, Ala-Opas M, Sankila A, Taari K.

Scand J Urol Nephrol. 2008;42(1):29-34. Epub 2007 Sep 11.

PMID:
17853030
5.

Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.

Prada PJ, Fernández J, Martinez AA, de la Rúa A, Gonzalez JM, Fernandez JM, Juan G.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):95-102.

PMID:
17707267
6.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

7.
8.

Management of the complications of radical prostatectomy.

Schraudenbach P, Bermejo CE.

Curr Urol Rep. 2007 May;8(3):197-202. Review.

PMID:
17459268
9.

Conservative management for postprostatectomy urinary incontinence.

Hunter KF, Glazener CM, Moore KN.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD001843. Review. Update in: Cochrane Database Syst Rev. 2012;1:CD001843.

PMID:
17443512
11.

Recovery of urinary continence following radical prostatectomy: the impact of prostate volume--analysis of data from the CaPSURE Database.

Konety BR, Sadetsky N, Carroll PR; CaPSURE Investigators.

J Urol. 2007 Apr;177(4):1423-5; discussion 1425-6.

PMID:
17382745
12.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.

J Clin Oncol. 2007 Mar 20;25(9):1038-42.

13.

Pathologic outcome of laparoscopic and open radical prostatectomy.

Dahl DM, He W, Lazarus R, McDougal WS, Wu CL.

Urology. 2006 Dec;68(6):1253-6. Epub 2006 Dec 4.

PMID:
17141845
14.

Rethinking 30-day mortality risk after radical prostatectomy.

Alibhai SM, Leach M, Tomlinson G, Krahn MD, Fleshner N, Naglie G.

Urology. 2006 Nov;68(5):1057-60.

PMID:
17113897
15.
16.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

18.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

19.

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.

Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7.

20.

Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.

Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA.

Expert Opin Investig Drugs. 2006 Mar;15(3):293-305. Review.

PMID:
16503765
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk